Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1318291 | 0.85 | DRD2 (0.62) | HTR1AKMT2ALMNADRD4 | |
| SCHEMBL3056156 | 0.81 | HTR1A (0.68) | HTR1AKMT2AMEN1MAPK1HTR7 | |
| SCHEMBL10401212 | 0.80 | LMNA (0.69) | LMNA | |
| SCHEMBL8445652 | 0.80 | DRD2 (0.66) | HTR1ADRD4 | |
| SCHEMBL8443516 | 0.79 | HTR1A (0.65) | HTR1AKMT2AMEN1MAPK1HTR7 | |
| SCHEMBL14007328 | 0.78 | HTR7 (0.69) | HTR1AKMT2AMEN1MAPK1HTR7 | |
| Benzene SCHEMBL10433203 | 0.78 | HTR1A (0.79) | HTR1AKMT2AHTR7 | |
| SCHEMBL3160665 | 0.78 | HTR1A (0.79) | HTR1AKMT2AHTR7 | |
| SCHEMBL5794272 | 0.77 | HTR1A (0.60) | HTR1AKMT2AMEN1MAPK1HTR7 | |
| SCHEMBL17946603 | 0.77 | CACNA1G (0.72) | HTR1AKMT2AMEN1MAPK1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275670-A1 | New Compounds VII | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | claimed |
| EP-2321276-A1 | NEW COMPOUNDS VII | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | claimed |
| WO-2009147219-A1 | NEW COMPOUNDS VII | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | claimed |
| EP-0395313-B1 | Tertiary alkyl functionalized piperazine derivatives | AMERICAN HOME PROD (US) | 1999-12-15 | — | — | EP | claimed |
| EP-0955296-A2 | Tertiary alkyl functionalized piperazine derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-10 | — | — | EP | claimed |
| US-4988814-A | Antidepressants and/or anxiolytic agents | AMERICAN HOME PRODUCTS CORP. (US) | 1991-01-29 | — | — | US | claimed |
| EP-0395313-A2 | Tertiary alkyl functionalized piperazine derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-10-31 | — | — | EP | claimed |
| US-20110275670-A1 | New Compounds VII | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | disclosed |
| EP-2321276-A1 | NEW COMPOUNDS VII | AstraZeneca AB (SE) | 2011-05-18 | — | — | EP | disclosed |
| WO-2009147219-A1 | NEW COMPOUNDS VII | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | disclosed |
| EP-0395313-B1 | Tertiary alkyl functionalized piperazine derivatives | AMERICAN HOME PROD (US) | 1999-12-15 | — | — | EP | disclosed |
| EP-0955296-A2 | Tertiary alkyl functionalized piperazine derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-11-10 | — | — | EP | disclosed |
| US-4988814-A | Antidepressants and/or anxiolytic agents | AMERICAN HOME PRODUCTS CORP. (US) | 1991-01-29 | — | — | US | disclosed |
| EP-0395313-A2 | Tertiary alkyl functionalized piperazine derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275670-A1 | New Compounds VII | GPR119, GLP1R, GIPR | HTR1A 865/4885KMT2A 3896/4885MEN1 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.